Hyper-reactive platelets and type 2 diabetes.
10.11817/j.issn.1672-7347.2022.210271
- Author:
Yi ZHANG
1
;
Huamei ZHOU
2
Author Information
1. Department of Endocrinology, People's Hospital of Nanchuan, Chongqing 408400, China. 258521541@qq.com.
2. Department of Endocrinology, People's Hospital of Nanchuan, Chongqing 408400, China. huamei2030@126.com.
- Publication Type:Journal Article
- Keywords:
hyper-reactive platelets;
macrovascular complications;
metabolic dysfunctions;
prothrombotic state;
type 2 diabetes
- MeSH:
Blood Platelets;
Diabetes Mellitus, Type 2/drug therapy*;
Humans;
Hyperglycemia/complications*;
Insulin Resistance;
Obesity/complications*
- From:
Journal of Central South University(Medical Sciences)
2022;47(3):374-383
- CountryChina
- Language:English
-
Abstract:
Type 2 diabetes mellitus is a progressive process. With the course of the disease progress, microvascular and macrovascular complications always happen. Thrombotic events caused by macrovascular complications, including coronary heart diseases and cerebrovascular diseases, are the main fatal factor for the patients with type 2 diabetes. Endothelial dysfunction, coagulative activation, impaired fibrinolysis, together with hyper-reactive platelets contribute to the diabetic prothrombotic state, which is strongly related to the macrovascular complications. In particular, the hyper-reactive platelets play a fundamental role among them. Type 2 diabetes is characterized by several metabolic dysfunctions such as hyperglycemia, insulin resistance and shortage, oxidative stress, systemic inflammation, obesity, and dyslipidemia. These metabolic dysfunctions work together to promote the formation of hyper-reactive platelets, which are distinctive in type 2 diabetes. The regular antiplatelet drugs, like aspirin, show limited inhibitory effect on them. Hence, studying the mechanism behind the hyper-reactive platelets could provide a brand-new view on the prevention of macrovascular complications and cardiovascular events in type 2 diabetes.
